Terminan

Terminan contains Temozolomide, an oral chemotherapy medication primarily used in the treatment of certain brain tumors, including glioblastoma multiforme and anaplastic astrocytoma. Temozolomide belongs to the class of alkylating agents, which work by damaging the DNA of cancer cells, preventing them from dividing and leading to cell death.

Temozolomide has become a standard of care in combination with radiotherapy or as maintenance therapy after initial treatment, offering improved survival rates and better disease management for brain tumor patients.

Uses of Terminan

✅ Glioblastoma Multiforme (GBM) — Used as the first-line treatment in combination with radiotherapy for newly diagnosed patients and as monotherapy for recurrent GBM.
✅ Anaplastic Astrocytoma — Approved for use in adults with refractory or relapsed high-grade gliomas.
✅ Other Off-Label Uses — Sometimes explored in clinical trials for other types of cancers, under oncologist supervision.

Key Benefits

• Oral chemotherapy: Easy-to-administer capsule form avoids the need for intravenous infusions.

• Proven survival benefit: Extends progression-free and overall survival in brain tumor patients.

• Blood-brain barrier penetration: Specifically designed to reach tumors within the brain.

• Combination therapy friendly: Works effectively alongside radiotherapy.

How Terminan Works

Terminan’s active ingredient, Temozolomide, is an alkylating agent that is converted in the body to its active form, MTIC (monomethyl triazeno imidazole carboxamide). This compound introduces methyl groups into the DNA of cancer cells, causing DNA strand breaks and ultimately leading to cell death.

Because brain tumors are notoriously difficult to treat due to the protective blood-brain barrier, Temozolomide’s ability to cross into the brain makes it uniquely valuable in neuro-oncology.